Inactive Instrument
Pluristem Therapeutics Inc. Stock Nasdaq
Stocks
US72940R1023
Biotechnology & Medical Research
| Market Cap | 12.22M 10.85M 10.15M 9.2M 17.38M 1.18B 17.5M 122M 47.43M 601M 45.87M 44.89M 1.93B | P/E 2025 |
-1.39x | P/E 2026 | -0.85x |
|---|---|---|---|---|---|
| Enterprise Value | 39.33M 34.91M 32.67M 29.61M 55.93M 3.79B 56.33M 392M 153M 1.93B 148M 144M 6.22B | EV / Sales 2025 |
39,078,124x | EV / Sales 2026 | 48,878,101x |
| Free-Float |
57.48% | Yield 2025 * |
-
| Yield 2026 | - |
| 1 day | +11.70% |
| Manager | Title | Age | Since |
|---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 54 | 29/03/2017 |
Liat Zalts
DFI | Director of Finance/CFO | 42 | 01/12/2022 |
Ori Shalem
COO | Chief Operating Officer | - | 01/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Yaky Yanay
BRD | Director/Board Member | 54 | 01/02/2015 |
| Director/Board Member | 56 | 06/01/2021 | |
| Director/Board Member | 64 | 01/06/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +11.70% | -24.18% | - | - | 12.78M | ||
| +4.16% | +4.16% | +49.37% | +94.17% | 74.31B | ||
| +2.76% | -1.60% | +22.80% | +78.53% | 56.95B | ||
| +0.24% | -1.34% | +3.41% | +34.31% | 48.3B | ||
| -3.76% | -2.25% | +329.09% | +698.20% | 44.51B | ||
| -2.30% | -3.35% | +26.81% | +30.88% | 43.8B | ||
| +0.31% | -0.68% | +5.30% | +108.64% | 41.12B | ||
| -0.11% | +1.96% | +9.19% | +52.66% | 31.07B | ||
| -2.07% | +1.16% | +35.00% | +26.28% | 28.97B | ||
| -1.96% | -2.88% | -8.97% | -13.92% | 24.53B | ||
| Average | +0.90% | -0.78% | +52.44% | +123.31% | 43.73B | |
| Weighted average by Cap. | +0.28% | -0.94% | +56.54% | +132.34% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 1.34 1.19 1.11 1.01 1.9 128.79 1.91 13.33 5.18 65.7 5.01 4.91 211.21 | 1.02 0.9 0.84 0.77 1.44 97.94 1.46 10.14 3.94 49.96 3.81 3.73 160.62 |
| Net income | -22.58M -20.05M -18.76M -17M -32.11M -2.18B -32.35M -225M -87.64M -1.11B -84.77M -82.95M -3.57B | -23.82M -21.15M -19.79M -17.94M -33.87M -2.3B -34.12M -238M -92.44M -1.17B -89.41M -87.5M -3.77B |
| Net Debt | 13.44M 11.93M 11.16M 10.12M 19.11M 1.3B 19.25M 134M 52.14M 661M 50.44M 49.36M 2.12B | 27.11M 24.07M 22.52M 20.41M 38.55M 2.61B 38.83M 270M 105M 1.33B 102M 99.58M 4.29B |
Employees
-
















